Vanda Pharmaceuticals ((VNDA)) announced an update on their ongoing clinical study.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Study Overview: The study titled ‘Crossover Bioequivalence Study of 12 mg VHX-896 and Iloperidone Tablets Under Steady-State Conditions’ aims to compare the pharmacokinetics and pharmacodynamics of VHX-896 and iloperidone. It also evaluates the safety and tolerability of these drugs in patients with schizophrenia or bipolar I disorder, highlighting its significance in improving treatment options for these conditions.
Intervention/Treatment: The study tests two oral tablet drugs, VHX-896 and iloperidone, intended to manage symptoms of schizophrenia and bipolar I disorder.
Study Design: This is a Phase 1 interventional study with a randomized, crossover model. There is no masking involved, and the primary purpose is treatment, ensuring clear and direct evaluation of the drug effects.
Study Timeline: The study began on July 2, 2024, and was last updated on September 15, 2025. These dates are crucial as they mark the progression and recent completion of the study, providing timely data for analysis.
Market Implications: The completion of this study could positively influence Vanda Pharmaceuticals’ stock performance by showcasing their commitment to advancing treatment for psychiatric disorders. This update might also affect investor sentiment positively, as successful results could position Vanda ahead of competitors in the psychiatric treatment market.
The study is completed, with further details available on the ClinicalTrials portal.